- call +1-201-465-4211
- email sales@mrinsights.biz
Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of damaged tissues in the human body. An induced pluripotent stem cells, or iPSCs, are taken from any tissue (usually skin or blood) from a child or an adult and is genetically modified to behave like pluripotent stem cells or embryonic stem cells.
Scope of the Report:
iPSCs market is in emerging state mainly due to its ability to make any cell or tissue the body might need to encounter wide range of diseases like diabetes, spinal cord injury, leukaemia or heart disease, these cells can potentially be customized to provide a perfect genetic match for any patient.
The global Induced Pluripotent Stem Cells market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Induced Pluripotent Stem Cells.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Induced Pluripotent Stem Cells market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Induced Pluripotent Stem Cells market by product type and applications/end industries.
Market Segment by Companies, this report covers
Fujifilm Holding Corporation
Astellas Pharma Inc
Fate Therapeutics, Inc
Bristol-Myers Squibb Company
ViaCyte, Inc
Celgene Corporation
Aastrom Biosciences, Inc
Acelity Holdings, Inc
StemCells, Inc
Japan Tissue Engineering Co., Ltd
Organogenesis Inc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
Market Segment by Applications, can be divided into
Academic Research
Drug Development And Discovery
Toxicity Screening
Regenerative Medicine
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Induced Pluripotent Stem Cells Market Overview
1.1 Product Overview and Scope of Induced Pluripotent Stem Cells
1.2 Classification of Induced Pluripotent Stem Cells by Types
1.2.1 Global Induced Pluripotent Stem Cells Revenue Comparison by Types (2017-2023)
1.2.2 Global Induced Pluripotent Stem Cells Revenue Market Share by Types in 2017
1.2.3 Hepatocytes
1.2.4 Fibroblasts
1.2.5 Keratinocytes
1.2.6 Amniotic Cells
1.2.7 Others
1.3 Global Induced Pluripotent Stem Cells Market by Application
1.3.1 Global Induced Pluripotent Stem Cells Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Academic Research
1.3.3 Drug Development And Discovery
1.3.4 Toxicity Screening
1.3.5 Regenerative Medicine
1.4 Global Induced Pluripotent Stem Cells Market by Regions
1.4.1 Global Induced Pluripotent Stem Cells Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Induced Pluripotent Stem Cells Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Induced Pluripotent Stem Cells Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Induced Pluripotent Stem Cells Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Induced Pluripotent Stem Cells Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Induced Pluripotent Stem Cells Status and Prospect (2013-2023)
1.5 Global Market Size of Induced Pluripotent Stem Cells (2013-2023)
2 Manufacturers Profiles
2.1 Fujifilm Holding Corporation
2.1.1 Business Overview
2.1.2 Induced Pluripotent Stem Cells Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.2 Astellas Pharma Inc
2.2.1 Business Overview
2.2.2 Induced Pluripotent Stem Cells Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Astellas Pharma Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.3 Fate Therapeutics, Inc
2.3.1 Business Overview
2.3.2 Induced Pluripotent Stem Cells Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Fate Therapeutics, Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bristol-Myers Squibb Company
2.4.1 Business Overview
2.4.2 Induced Pluripotent Stem Cells Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.5 ViaCyte, Inc
2.5.1 Business Overview
2.5.2 Induced Pluripotent Stem Cells Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ViaCyte, Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.6 Celgene Corporation
2.6.1 Business Overview
2.6.2 Induced Pluripotent Stem Cells Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Celgene Corporation Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.7 Aastrom Biosciences, Inc
2.7.1 Business Overview
2.7.2 Induced Pluripotent Stem Cells Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Aastrom Biosciences, Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.8 Acelity Holdings, Inc
2.8.1 Business Overview
2.8.2 Induced Pluripotent Stem Cells Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Acelity Holdings, Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.9 StemCells, Inc
2.9.1 Business Overview
2.9.2 Induced Pluripotent Stem Cells Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 StemCells, Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.10 Japan Tissue Engineering Co., Ltd
2.10.1 Business Overview
2.10.2 Induced Pluripotent Stem Cells Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Japan Tissue Engineering Co., Ltd Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.11 Organogenesis Inc
2.11.1 Business Overview
2.11.2 Induced Pluripotent Stem Cells Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Organogenesis Inc Induced Pluripotent Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
3 Global Induced Pluripotent Stem Cells Market Competition, by Players
3.1 Global Induced Pluripotent Stem Cells Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Induced Pluripotent Stem Cells Players Market Share
3.2.2 Top 10 Induced Pluripotent Stem Cells Players Market Share
3.3 Market Competition Trend
4 Global Induced Pluripotent Stem Cells Market Size by Regions
4.1 Global Induced Pluripotent Stem Cells Revenue and Market Share by Regions
4.2 North America Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
4.3 Europe Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
4.5 South America Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
5 North America Induced Pluripotent Stem Cells Revenue by Countries
5.1 North America Induced Pluripotent Stem Cells Revenue by Countries (2013-2018)
5.2 USA Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
5.3 Canada Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
5.4 Mexico Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
6 Europe Induced Pluripotent Stem Cells Revenue by Countries
6.1 Europe Induced Pluripotent Stem Cells Revenue by Countries (2013-2018)
6.2 Germany Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
6.3 UK Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
6.4 France Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
6.5 Russia Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
6.6 Italy Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Induced Pluripotent Stem Cells Revenue by Countries
7.1 Asia-Pacific Induced Pluripotent Stem Cells Revenue by Countries (2013-2018)
7.2 China Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
7.3 Japan Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
7.4 Korea Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
7.5 India Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
8 South America Induced Pluripotent Stem Cells Revenue by Countries
8.1 South America Induced Pluripotent Stem Cells Revenue by Countries (2013-2018)
8.2 Brazil Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
8.3 Argentina Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
8.4 Colombia Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Induced Pluripotent Stem Cells by Countries
9.1 Middle East and Africa Induced Pluripotent Stem Cells Revenue by Countries (2013-2018)
9.2 Saudi Arabia Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
9.3 UAE Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
9.4 Egypt Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
9.5 Nigeria Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
9.6 South Africa Induced Pluripotent Stem Cells Revenue and Growth Rate (2013-2018)
10 Global Induced Pluripotent Stem Cells Market Segment by Type
10.1 Global Induced Pluripotent Stem Cells Revenue and Market Share by Type (2013-2018)
10.2 Global Induced Pluripotent Stem Cells Market Forecast by Type (2018-2023)
10.3 Hepatocytes Revenue Growth Rate (2013-2023)
10.4 Fibroblasts Revenue Growth Rate (2013-2023)
10.5 Keratinocytes Revenue Growth Rate (2013-2023)
10.6 Amniotic Cells Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global Induced Pluripotent Stem Cells Market Segment by Application
11.1 Global Induced Pluripotent Stem Cells Revenue Market Share by Application (2013-2018)
11.2 Induced Pluripotent Stem Cells Market Forecast by Application (2018-2023)
11.3 Academic Research Revenue Growth (2013-2018)
11.4 Drug Development And Discovery Revenue Growth (2013-2018)
11.5 Toxicity Screening Revenue Growth (2013-2018)
11.6 Regenerative Medicine Revenue Growth (2013-2018)
12 Global Induced Pluripotent Stem Cells Market Size Forecast (2018-2023)
12.1 Global Induced Pluripotent Stem Cells Market Size Forecast (2018-2023)
12.2 Global Induced Pluripotent Stem Cells Market Forecast by Regions (2018-2023)
12.3 North America Induced Pluripotent Stem Cells Revenue Market Forecast (2018-2023)
12.4 Europe Induced Pluripotent Stem Cells Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Induced Pluripotent Stem Cells Revenue Market Forecast (2018-2023)
12.6 South America Induced Pluripotent Stem Cells Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Induced Pluripotent Stem Cells Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Induced Pluripotent Stem Cells Picture
Table Product Specifications of Induced Pluripotent Stem Cells
Table Global Induced Pluripotent Stem Cells and Revenue (Millio
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
